高度赞扬
发表于 2025-3-30 12:07:17
http://reply.papertrans.cn/23/2211/221080/221080_51.png
Deject
发表于 2025-3-30 16:26:23
http://reply.papertrans.cn/23/2211/221080/221080_52.png
细丝
发表于 2025-3-30 20:24:20
http://reply.papertrans.cn/23/2211/221080/221080_53.png
合唱团
发表于 2025-3-30 23:38:23
Statistical Tools for Subset Analysis in Clinical Trialsical to design future studies and treat future patients on this basis? Does this also hold for clinical trials of cardiovascular disease or cancer prevention which may involve enormous numbers of patients and cost tens of millions of dollars? Is this sensible statistically?
暗语
发表于 2025-3-31 01:09:17
http://reply.papertrans.cn/23/2211/221080/221080_55.png
整洁漂亮
发表于 2025-3-31 05:30:56
http://reply.papertrans.cn/23/2211/221080/221080_56.png
Aromatic
发表于 2025-3-31 10:28:12
Cancer Clinical Trials978-3-642-83419-6Series ISSN 0080-0015 Series E-ISSN 2197-6767
刺激
发表于 2025-3-31 13:31:49
Journal of Neural Transmission. Supplementacularly so as the number of staff increases because of the need to control standards and to maintain consistent approaches. Statistical work is no exception, whether concerned with the design or the analysis of clinical trials.
流出
发表于 2025-3-31 18:16:58
https://doi.org/10.1007/978-3-642-83419-6adjuvant therapy; breast cancer; cancer; cancer prevention; cancer treatment; clinical trial; morbidity; pr
持久
发表于 2025-3-31 22:32:13
http://reply.papertrans.cn/23/2211/221080/221080_60.png